Beyondspring Inc
BYSI2.190USD
+0.120+5.80%
Market hours （ET）Quotes delayed by 15 min
88.29MMarket Cap
LossP/E TTM
More Details of Beyondspring Inc Company
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Company Info
Ticker SymbolBYSI
Company nameBeyondspring Inc
IPO dateMar 09, 2017
CEODr. Lan Huang, Ph.D.
Number of employees40
Security typeOrdinary Share
Fiscal year-endMar 09
Address100 Campus Drive, West Side, 4Th Floor
CityFLORHAM PARK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07932
Phone16465284184
Websitehttps://www.beyondspringpharma.com/en/
Ticker SymbolBYSI
IPO dateMar 09, 2017
CEODr. Lan Huang, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Mr. Matthew Kirkby
Mr. Matthew Kirkby
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 19
Updated: Sat, Jul 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Decheng Capital LLC
12.11%
Huang (Lan)
10.58%
Jia (Linqing)
4.43%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
71.30%
Shareholders
Shareholders
Proportion
Decheng Capital LLC
12.11%
Huang (Lan)
10.58%
Jia (Linqing)
4.43%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
71.30%
Shareholder Types
Shareholders
Proportion
Individual Investor
15.26%
Venture Capital
12.11%
Investment Advisor
1.69%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.13%
Bank and Trust
0.09%
Research Firm
0.03%
Other
70.33%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
62
11.96M
29.67%
-626.00K
2025Q1
65
11.44M
28.38%
-1.18M
2024Q4
71
11.41M
28.30%
-5.42M
2024Q3
73
15.85M
39.34%
-1.46M
2024Q2
85
16.08M
39.89%
-939.10K
2024Q1
128
16.18M
41.46%
-1.22M
2023Q4
143
15.76M
40.39%
-1.74M
2023Q3
172
17.23M
44.26%
-3.36M
2023Q2
182
17.28M
44.39%
-4.16M
2023Q1
198
17.53M
45.04%
-4.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Decheng Capital LLC
4.88M
12.11%
-75.49K
-1.52%
Mar 31, 2025
Huang (Lan)
4.26M
10.58%
--
--
Feb 28, 2025
Jia (Linqing)
1.78M
4.43%
+4.00
+0.00%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
115.97K
0.29%
-1.09K
-0.93%
Mar 31, 2025
BlackRock Financial Management, Inc.
90.54K
0.22%
--
--
Mar 31, 2025
Fabbio (Patrick)
53.86K
0.13%
+29.27K
+119.03%
Feb 28, 2025
Majeti (Jiangwen)
50.91K
0.13%
--
--
Feb 28, 2025
UBS Switzerland AG
34.93K
0.09%
-17.48K
-33.35%
Mar 31, 2025
Tanaka Capital Management, Inc.
26.30K
0.07%
-3.18K
-10.78%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
